CD147 supports paclitaxel resistance via interacting with RanBP1

Gang Nan1,6, Shu-Hua Zhao2,6, Ting Wang3,6, Dong Chao4,6, Ruo-Fei Tian1, Wen-Jing Wang1, Xin Fu1, Peng Lin1, Ting Guo1, Bin Wang1, Xiu-Xuan Sun1, Xi Chen5, Zhi-Nan Chen1,6, Shi-Jie Wang1,6 and Hong-Yong Cui1,6

© The Author(s) 2021

Oncogene (2022) 41:983–996; https://doi.org/10.1038/s41388-021-02143-3

INTRODUCTION

Microtubules, highly dynamic components of the cytoskeleton, participate in multiple cellular activities. Assembly of mitotic microtubules into a bipolar spindle is essential for balanced chromosome distribution to newborn daughter cells at mitosis. Dysregulation of microtubule dynamics contributes to the development of serious diseases, including cancer. Microtubule dynamics is one of the major targets for chemotherapeutic agents. Paclitaxel (Taxol®), a member of the taxane class, is one of the most widely used chemotherapeutic agents, together with doxorubicin and cisplatin, and is first- or second-line treatment for several types of cancer, including ovarian cancer, NSCLC, breast cancer and cervical cancer. Since its approval by the FDA in 1992 for the treatment of ovarian cancer, the use of paclitaxel has led to dramatically improved in the duration and quality of life for many cancer patients, however, the majority eventually develop progressive disease after initially responding to paclitaxel treatment. Primary or acquired resistance, which often limits the clinical utility of paclitaxel, represents a major obstacle to improving the overall response and survival of cancer patients. While a variety of mechanisms have been linked to paclitaxel resistance, including overexpression of ATP-dependent translocase ABCB1 [1], mutations in drug binding sites on tubulin [2–7], alterations in tubulin isotype distribution [8], aberrant expression of noncoding RNAs [9], impairment of apoptotic pathways [10] and altered expression of microtubule regulatory proteins [11], the mechanisms responsible for paclitaxel resistance are far from clear.

CD147, a type I transmembrane protein, belongs to the immunoglobulin superfamily. CD147, also known as extracellular matrix metalloproteinase inducer, is a multifunctional cell adhesion molecule that plays important roles in both physiological and pathological conditions, including reproduction, development, immunological responses, infectious diseases and malignant tumors [12]. CD147 is overexpressed in multiple cancer tissues, including ovarian cancer, NSCLC, breast cancer, cervical cancer and hepatocellular carcinoma [13]. Mounting evidence indicates that CD147 regulates cancer cell migration [14], though the great success of paclitaxel, the variable response of patients to the drug limits its clinical utility and the precise mechanisms underlying the variable response to paclitaxel remain largely unknown. This study aims to verify the role and the underlying mechanisms of CD147 in paclitaxel resistance. Immunostaining was used to analyze human non-small-cell lung cancer (NSCLC) and ovarian cancer tissues. RNA-sequencing was used to identify downstream effectors. Annexin V-FITC/propidium iodide and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining were used to detect apoptosis. Co-immunoprecipitation (Co-IP), fluorescence resonance energy transfer (FRET) and surface plasmon resonance (SPR) were performed to determine protein interactions. Fluorescence recovery after photobleaching (FRAP) was performed to measure the speed of microtubule turnover. Xenograft tumor model was established to evaluate sensitivity of cancer cells to paclitaxel in vivo. In vitro and in vivo assays showed that silencing CD147 sensitized the cancer cells to paclitaxel treatment. CD147 protected cancer cells from paclitaxel-induced caspase-3 mediated apoptosis regardless of p53 status. Truncation analysis showed that the intracellular domain of CD147 (CD147ICD) was indispensable for CD147-regulated sensitivity to paclitaxel. Via screening the interacting proteins of CD147ICD, Ran binding protein 1 (RanBP1) was identified to interact with CD147ICD via its C-terminal tail. Furthermore, we showed that RanBP1 mediated CD147-regulated microtubule stability and dynamics as well as response to paclitaxel treatment. These results demonstrated that CD147 regulated paclitaxel response by interacting with the C-terminal tail of RanBP1 and targeting CD147 may be a promising strategy for preventing paclitaxel resistant.

Though the great success of paclitaxel, the variable response of patients to the drug limits its clinical utility and the precise mechanisms underlying the variable response to paclitaxel remain largely unknown. This study aims to verify the role and the underlying mechanisms of CD147 in paclitaxel resistance. Immunostaining was used to analyze human non-small-cell lung cancer (NSCLC) and ovarian cancer tissues. RNA-sequencing was used to identify downstream effectors. Annexin V-FITC/propidium iodide and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining were used to detect apoptosis. Co-immunoprecipitation (Co-IP), fluorescence resonance energy transfer (FRET) and surface plasmon resonance (SPR) were performed to determine protein interactions. Fluorescence recovery after photobleaching (FRAP) was performed to measure the speed of microtubule turnover. Xenograft tumor model was established to evaluate sensitivity of cancer cells to paclitaxel in vivo. In vitro and in vivo assays showed that silencing CD147 sensitized the cancer cells to paclitaxel treatment. CD147 protected cancer cells from paclitaxel-induced caspase-3 mediated apoptosis regardless of p53 status. Truncation analysis showed that the intracellular domain of CD147 (CD147ICD) was indispensable for CD147-regulated sensitivity to paclitaxel. Via screening the interacting proteins of CD147ICD, Ran binding protein 1 (RanBP1) was identified to interact with CD147ICD via its C-terminal tail. Furthermore, we showed that RanBP1 mediated CD147-regulated microtubule stability and dynamics as well as response to paclitaxel treatment. These results demonstrated that CD147 regulated paclitaxel response by interacting with the C-terminal tail of RanBP1 and targeting CD147 may be a promising strategy for preventing paclitaxel resistant.

© The Author(s) 2021

Oncogene (2022) 41:983–996; https://doi.org/10.1038/s41388-021-02143-3

INTRODUCTION

Microtubules, highly dynamic components of the cytoskeleton, participate in multiple cellular activities. Assembly of mitotic microtubules into a bipolar spindle is essential for balanced chromosome distribution to newborn daughter cells at mitosis. Dysregulation of microtubule dynamics contributes to the development of serious diseases, including cancer. Microtubule dynamics is one of the major targets for chemotherapeutic agents. Paclitaxel (Taxol®), a member of the taxane class, is one of the most widely used chemotherapeutic agents, together with doxorubicin and cisplatin, and is first- or second-line treatment for several types of cancer, including ovarian cancer, NSCLC, breast cancer and cervical cancer. Since its approval by the FDA in 1992 for the treatment of ovarian cancer, the use of paclitaxel has led to dramatically improved in the duration and quality of life for many cancer patients, however, the majority eventually develop progressive disease after initially responding to paclitaxel treatment. Primary or acquired resistance, which often limits the clinical utility of paclitaxel, represents a major obstacle to improving the overall response and survival of cancer patients. While a variety of mechanisms have been linked to paclitaxel resistance, including overexpression of ATP-dependent translocase ABCB1 [1], mutations in drug binding sites on tubulin [2–7], alterations in tubulin isotype distribution [8], aberrant expression of noncoding RNAs [9], impairment of apoptotic pathways [10] and altered expression of microtubule regulatory proteins [11], the mechanisms responsible for paclitaxel resistance are far from clear.

CD147, a type I transmembrane protein, belongs to the immunoglobulin superfamily. CD147, also known as extracellular matrix metalloproteinase inducer, is a multifunctional cell adhesion molecule that plays important roles in both physiological and pathological conditions, including reproduction, development, immunological responses, infectious diseases and malignant tumors [12]. CD147 is overexpressed in multiple cancer tissues, including ovarian cancer, NSCLC, breast cancer, cervical cancer and hepatocellular carcinoma [13]. Mounting evidence indicates that CD147 regulates cancer cell migration [14],
invasion [15], adhesion [16], metastasis [17], angiogenesis [18], apoptosis [19, 20], autophagy [21] and proliferation [22]. Furthermore, studies showed that CD147 was associated with poor response to paclitaxel [23, 24] and inhibition of CD147 by siRNA increased chemosensitivity to paclitaxel [23], however, the mechanisms underlying CD147-mediated resistance to paclitaxel-based treatment are largely unknown.

In this study, we validated the association between CD147 expression and paclitaxel resistance in ovarian cancer and NSCLC. We demonstrated that CD147 protects cancer cells from paclitaxel-induced caspase-3-mediated apoptosis regardless of p53 status. Mechanically, we characterized RanBP1 as a binding partner for CD147 [23, 24]. Via binding to the C-terminal tail of RanBP1, CD147 decreased Ran-GTP and regulated microtubule stability and dynamics, which contributed to the resistance of paclitaxel treatment. These findings thus reveal CD147 as a critical regulator of paclitaxel sensitivity and have important implications in cancer chemotherapy.

RESULTS
High expression of CD147 correlates with paclitaxel resistance
To investigate whether the expression status of CD147 is related to paclitaxel response, we determined CD147 expression using IHC in 25 NSCLC tissues (13 with no response to paclitaxel-based treatment and 12 that responded to paclitaxel-based treatment) and 50 ovarian cancer tissues (20 with no response to paclitaxel-based treatment and 30 that responded to paclitaxel-based treatment). As shown in Fig. 1A, B and Supplementary Tables 1–2, we found that the expression of CD147 was significantly higher in the paclitaxel resistant group compared to the paclitaxel sensitive group. We also generated paclitaxel resistant A549 cells (A549-R, Fig. 1C) and SK-OV-3 cells (SK-OV-3-R, Fig. 1D) and determined the expression of CD147. We found that CD147 was increased in A549-R and SK-OV-3-R cells compared to the parent cells (Fig. 1E, F). All these results indicate that CD147 may contribute to paclitaxel resistance.

CD147 impairs induction of apoptosis by paclitaxel
To further validate the role of CD147 in paclitaxel response, we generated SK-OV-3 and A549 CD147 knockdown cells (Fig. 2A and Supplementary Fig. 1A) and challenged the cells with paclitaxel. We found that paclitaxel treatment induced apoptosis (Fig. 2B–D and Supplementary Fig. 1B–D), which was consistent with the previous studies [25, 26]. Compared to the parent cells, the percentage of apoptotic cells was much higher in the CD147 knockdown cells (Fig. 2B–D and Supplementary Fig. 1B–D), which was observed in both the tested cell lines. As paclitaxel can induce mitotic arrest, we also checked the cell cycle progression. We found that paclitaxel induced G2/M phase arrest and this effect was more significant in CD147 knockdown cells (Fig. 2E and Supplementary Fig. 1E). In addition, we found that cells overexpressing CD147 were less sensitive to paclitaxel treatment (Supplementary Fig. 2). Furthermore, we performed a xenograft assay in immunodeficient mice with cells from the ovarian cancer cell line SK-OV-3 or NSCLC cell line A549 expressing scramble shRNA or shRNAs targeting CD147 (shCD147) and treated the mice with saline or paclitaxel (Fig. 2F). We found that paclitaxel treatment could decrease tumor growth. Notably, although CD147 knockdown per se delayed tumor progression to a lesser extent, the combination of CD147 knockdown and paclitaxel treatment significantly shrunk the tumors (Fig. 2G and Supplementary Fig. 1F–H), suggesting that CD147 knockdown sensitizes cancer cells to paclitaxel. Immunohistochemical staining showed that shCD147 plus paclitaxel group had weaker Ki67 staining compared to the scramble shRNA plus paclitaxel group (Fig. 2H). All these results demonstrated that CD147 decreases sensitivity of cancer cells to paclitaxel.

Caspase-3 regulates apoptosis induction by paclitaxel in CD147-silenced cells
Because caspase-3 enzyme is a member of the family of endoproteases which regulate apoptosis signaling network. We determined whether caspase-3 regulated paclitaxel-induced apoptosis in CD147 knockdown cells. We found that siRNAs targeting caspase-3 as well as pan caspase inhibitor Z-VAD-FMK could relieve paclitaxel-induced apoptosis in CD147 knockdown cells (Fig. 3 and Supplementary 3). Notably, we found that CD147 knockdown sensitized cancer cells to paclitaxel and Z-VAD-FMK could relieve paclitaxel-induced apoptosis in A549 cells treated with p53 inhibitor Pifithrin-α as well as SK-OV-3 cells overexpressing p53 (Supplementary Fig. 4). All these results suggest that CD147 protects cancer cells from paclitaxel-induced caspase-3 mediated apoptosis regardless of p53 status.

CD147 regulates microtubule dynamics
To explore the mechanisms by which CD147 regulates the sensitivity of cancer cells to paclitaxel, we employed gene expression profiling in cancer cells expressing scramble shRNA or shRNAs targeting CD147, which were challenged with paclitaxel. In the NSCLC cell line A549, of the 2059 differentially expressed genes (DEGs) identified, 1103 genes were upregulated and 956 genes were down-regulated (Fig. 4A and Supplementary Fig. 5A). Gene set enrichment analysis showed that the gene set apoptosis was upregulated in A549_shCD147 cells (Supplementary Fig. 5B) and the gene sets mitotic spindle and cell cycle were upregulated in A549_shCtrl cells (Fig. 4B). In ovarian cancer cell line SK-OV-3, of the 6072 DEGs identified, 3403 genes were upregulated and 2669 genes were down-regulated (Supplementary Fig. 5C, D). Gene set enrichment analysis showed that the gene set mitotic cell cycle arrest was upregulated in SK-OV-3_shCD147 cells and the gene set mitotic spindle was upregulated in SK-OV-3_shCtrl cells (Supplementary Fig. 5E). All these data indicate that CD147 may alleviate the cytotoxicity of paclitaxel by regulating spindle formation. Given paclitaxel exerts its action by directly inducing the formation of static microtubules and spindle formation is driven by dynamic microtubules and RanGTP gradient, we checked the effects of CD147 knockdown on microtubule dynamics and RanGTP. We applied live-cell microscopy to record microtubule dynamics in A549 cells stably transfected GFP-α-tubulin. We used the FRAP technique to measure the speed of microtubule turnover. As expected, cells responded to paclitaxel treatment with a reduced mobile fraction after photobleaching. In contrast, cells with CD147 knockdown were more responsive to paclitaxel (Fig. 4C). In the second approach, we analyzed two forms of posttranslational modifications of α-tubulin, acetylated α-tubulin at Lys40 and detyrosinated α-tubulin, which were less dynamic and more stable. Consistent with the pharmacological activity of paclitaxel, we found that paclitaxel treatment resulted in increased acetylated α-tubulin and detyrosinated α-tubulin, indicating increased microtubule stability. Notably, we found that acetylated α-tubulin and detyrosinated α-tubulin induced by paclitaxel treatment were further increased in CD147 knockdown cells (Fig. 4D and Supplementary Fig. 5F). Thus, these results confirmed that CD147 knockdown promoted paclitaxel-induced stabilization of microtubules. In addition, we examined the Ran-GTP level and found that CD147 knockdown cells had higher Ran-GTP level (Fig. 4E). All these results suggest that silence of CD147 in the presence of paclitaxel augments microtubule stabilization and cytotoxicity.

The intracellular domain of CD147 (CD147ICD) is indispensable for CD147-regulated paclitaxel resistance
To determine which domain of CD147 is critical for regulating paclitaxel sensibility, we restored the expression of wild-type CD147 (CD147WT) or truncated CD147 lacking the intracellular domain (CD147ICD) in CD147 knockdown cells (Fig. 5A) and found that the cells expressing CD147ICD were more sensitive to...
Fig. 1 High expression of CD147 correlates with paclitaxel resistance. A–B Representative images of immunohistochemical staining of CD147 in NSCLC (A) and ovarian cancer (B) tissues. Scale bar = 200 μm. The p values were determined by Pearson’s chi-squared test. C–D Cytotoxic effects of increasing concentrations of paclitaxel in A549, A549-R (C), SK-OV-3 and SK-OV-3-R (D) cells. The half maximal inhibitory concentration (IC50) was obtained from three independent CCK-8 assays. E–F Western blot analysis of CD147 expression in the indicated cells. The graphs show semi-quantitative analysis of relative CD147 expression. The p values were determined by using two-tailed Student’s t test.
Fig. 2  Silence of CD147 potentiates paclitaxel-induced cytotoxicity. A Western blot analysis of CD147 expression in SK-OV-3 cells. B Apoptosis analysis of SK-OV-3 cells by flow cytometry. C Representative images of TUNEL staining in SK-OV-3 cells. Scale bar = 20 μm. The graph shows quantification of the percentage of TUNEL positive cells. D Western blot analysis of the indicated proteins in SK-OV-3 cells. The graphs show semi-quantitative analysis of relative cleaved PARP and cleaved caspase-3 expression. The p values in (C and D) were determined by using two-tailed Student’s t test. E Cell cycle distribution of SK-OV-3 cells. F Schematic representation of subcutaneous cancer xenografts, as well as the schedule of paclitaxel administration in the nude mouse model. n = 6 for each group. G Nude mice with subcutaneous SK-OV-3 xenografts were imaged in a Xenogen IVIS 200 system. H Representative images of immunochemistry staining of CD147 and Ki67 on subcutaneous SK-OV-3 xenografts. Scale bar = 200 μm. The graph summarizes the IHC score of Ki67 and the p value was determined by using Mann–Whitney U test.
Fig. 3  Caspase-3 regulates apoptosis induction by paclitaxel in CD147-silenced cells. A Analysis of apoptosis by flow cytometry. SK-OV-3 cells with stably silencing of CD147 (shCD147) or control cells (shCtrl) were transfected with siRNAs targeting caspase 3 (siCaspase 3) or scramble siRNA alone or in combination with 40 μM Z-VAD-FMK treatment. B Representative images of TUNEL staining of SK-OV-3 cells. Scale bar = 20 μm. The graph shows quantification of the percentage of TUNEL positive cells. C Western blot analysis of the indicated proteins in SK-OV-3 cells. The graphs show semi-quantitative analysis of relative cleaved PARP and cleaved caspase-3 expression. The p values in (B and C) were determined by using two-tailed Student’s t test.
Fig. 4 CD147 knockdown promotes paclitaxel-induced stabilization of microtubules. A Heatmap of DEGs in CD147 knockdown A549 cells (A549_shCD147) and control cells (A549_shCtrl). Cells were treated with 0.1 μM paclitaxel for 48 h. B Gene set enrichment analysis of DEGs. C Analysis of FRAP assay. The p values were determined by one-way ANOVA with Tukey’s post hoc test. D Western blot analysis of the indicated proteins in CD147 knockdown cells and control cells treated with or without 0.1 μM paclitaxel. The graphs show semi-quantitative analysis of relative acetyl-α-tubulin and detyrosinated α-tubulin expression. The p values were determined by using two-tailed Student’s t test. E Western blot analysis of Ran-GTP in CD147 knockdown cells and control cells.
paclitaxel treatment compared with the cells expressing CD147WT (Fig. 5B–D and Supplementary Fig. 6A–C). Furthermore, we restored the expression of wild-type CD147 (CD147WT), truncated CD147 lacking the extracellular domain (CD147ΔECD) or the intracellular domain of CD147 (CD147ICD) in CD147 knockdown cells (Fig. 5E) and found that the cells expressing CD147ΔECD or CD147ICD were less sensitive to paclitaxel treatment compared with the cells expressing CD147WT (Fig. 5F–H and Supplementary Fig. 6D, E). These results indicate that the intracellular domain of CD147 is responsible for CD147-regulated paclitaxel response.
CD147<sup>ICD</sup> interacts with RanBP1

We showed that CD147 regulates paclitaxel resistance via its intracellular domain. We next tried to identify the CD147<sup>ICD</sup>-associated molecules responsible for this regulation. A His pull-down assay was employed to capture the proteins interacting with CD147<sup>ICD</sup>, where purified His<sub>6</sub>-tagged CD147<sup>ICD</sup> was the bait (Supplementary Fig. 7A), and the lysates from A549 or SK-OV-3 cells were prey (Supplementary Fig. 7B). Through LC-MS/MS analysis, overlapping proteins interacting with the control resin were removed, and RanBP1 emerged as having the highest probability of being a candidate binding partner for CD147<sup>ICD</sup> (Fig. 6A, Supplementary Table 3). We showed that endogenous CD147 could form a complex with RanBP1 in SK-OV-3 cells (a reciprocal Co-IP assay, Fig. 6B) and A549 cells (Supplementary Fig. 7C). The co-localization of CD147 and RanBP1 in A549 cells (Fig. 6C) and SK-OV-3 cells (Supplementary Fig. 7D) as well as cancer tissues was confirmed via immunofluorescence staining (NSCLC tissue, Supplementary Fig. 7E; ovarian cancer tissue, Supplementary Fig. 7F). Notably, the co-localization of RanBP1 and CD147 was more significant when using a monoclonal antibody targeting the intracellular domain of CD147 (anti-CD147<sup>ICD</sup>) rather than the monoclonal antibody targeting the extracellular domain of CD147 (anti-CD147<sup>ECD</sup>). In addition, we showed that CD147<sup>ICD</sup> directly interacted with RanBP1 by using SPR assay with purified proteins (KD = 2.25 ± 0.12 μM, Fig. 6D). Furthermore, FRET assays showed that CD147<sup>WT</sup>, CD147<sup>ICD</sup> and CD147<sup>ECD</sup> but not CD147<sup>ICD</sup> could interact with RanBP1 in live cells (Fig. 6E). We also truncated RanBP1 (Supplementary Fig. 7G) and FRET assays showed that the C-terminal tail (amino acids 165–201) of RanBP1 mediates binding of RanBP1 to CD147 (Fig. 6F). Co-IP assays confirmed the interaction between the C-terminal tail of RanBP1 and CD147 in A549 cells (Supplementary Fig. 7H). All these results suggest that the intracellular domain of CD147 interacts with the C-terminal tail of RanBP1.

CD147 regulates microtubule stability via RanBP1

Since the Ran GTPase plays critical roles in regulating microtubule cytoskeleton dynamics and RanBP1 has been characterized as a coactivator of the Ran GTPase-activating protein (RanGAP1) and regulates Ran-GTP production, we investigated whether CD147 regulates microtubule stability and dynamics via RanBP1, we conducted a His pull-down assay to capture the proteins interacting with CD147<sup>ICD</sup>, where purified His<sub>6</sub>-tagged CD147<sup>ICD</sup> was the bait (Supplementary Fig. 7A), and the lysates from A549 or SK-OV-3 cells were prey (Supplementary Fig. 7B). Through LC-MS/MS analysis, overlapping proteins interacting with the control resin were removed, and RanBP1 emerged as having the highest probability of being a candidate binding partner for CD147<sup>ICD</sup> (Fig. 6A, Supplementary Table 3). We showed that endogenous CD147 could form a complex with RanBP1 in SK-OV-3 cells (a reciprocal Co-IP assay, Fig. 6B) and A549 cells (Supplementary Fig. 7C). The co-localization of CD147 and RanBP1 in A549 cells (Fig. 6C) and SK-OV-3 cells (Supplementary Fig. 7D) as well as cancer tissues was confirmed via immunofluorescence staining (NSCLC tissue, Supplementary Fig. 7E; ovarian cancer tissue, Supplementary Fig. 7F). Notably, the co-localization of RanBP1 and CD147 was more significant when using a monoclonal antibody targeting the intracellular domain of CD147 (anti-CD147<sup>ICD</sup>) rather than the monoclonal antibody targeting the extracellular domain of CD147 (anti-CD147<sup>ECD</sup>). In addition, we showed that CD147<sup>ICD</sup> directly interacted with RanBP1 by using SPR assay with purified proteins (KD = 2.25 ± 0.12 μM, Fig. 6D). Furthermore, FRET assays showed that CD147<sup>WT</sup>, CD147<sup>ICD</sup> and CD147<sup>ECD</sup> but not CD147<sup>ICD</sup> could interact with RanBP1 in live cells (Fig. 6E). We also truncated RanBP1 (Supplementary Fig. 7G) and FRET assays showed that the C-terminal tail (amino acids 165–201) of RanBP1 mediates binding of RanBP1 to CD147 (Fig. 6F). Co-IP assays confirmed the interaction between the C-terminal tail of RanBP1 and CD147 in A549 cells (Supplementary Fig. 7H). All these results suggest that the intracellular domain of CD147 interacts with the C-terminal tail of RanBP1.

CD147 regulates microtubule stability via RanBP1

Since the Ran GTPase plays critical roles in regulating microtubule cytoskeleton dynamics and RanBP1 has been characterized as a coactivator of the Ran GTPase-activating protein (RanGAP1) and regulates Ran-GTP production, we investigated whether CD147 regulates microtubule stability and dynamics via RanBP1, we conducted a His pull-down assay to capture the proteins interacting with CD147<sup>ICD</sup>, where purified His<sub>6</sub>-tagged CD147<sup>ICD</sup> was the bait (Supplementary Fig. 7A), and the lysates from A549 or SK-OV-3 cells were prey (Supplementary Fig. 7B). Through LC-MS/MS analysis, overlapping proteins interacting with the control resin were removed, and RanBP1 emerged as having the highest probability of being a candidate binding partner for CD147<sup>ICD</sup> (Fig. 6A, Supplementary Table 3). We showed that endogenous CD147 could form a complex with RanBP1 in SK-OV-3 cells (a reciprocal Co-IP assay, Fig. 6B) and A549 cells (Supplementary Fig. 7C). The co-localization of CD147 and RanBP1 in A549 cells (Fig. 6C) and SK-OV-3 cells (Supplementary Fig. 7D) as well as cancer tissues was confirmed via immunofluorescence staining (NSCLC tissue, Supplementary Fig. 7E; ovarian cancer tissue, Supplementary Fig. 7F). Notably, the co-localization of RanBP1 and CD147 was more significant when using a monoclonal antibody targeting the intracellular domain of CD147 (anti-CD147<sup>ICD</sup>) rather than the monoclonal antibody targeting the extracellular domain of CD147 (anti-CD147<sup>ECD</sup>). In addition, we showed that CD147<sup>ICD</sup> directly interacted with RanBP1 by using SPR assay with purified proteins (KD = 2.25 ± 0.12 μM, Fig. 6D). Furthermore, FRET assays showed that CD147<sup>WT</sup>, CD147<sup>ICD</sup> and CD147<sup>ECD</sup> but not CD147<sup>ICD</sup> could interact with RanBP1 in live cells (Fig. 6E). We also truncated RanBP1 (Supplementary Fig. 7G) and FRET assays showed that the C-terminal tail (amino acids 165–201) of RanBP1 mediates binding of RanBP1 to CD147 (Fig. 6F). Co-IP assays confirmed the interaction between the C-terminal tail of RanBP1 and CD147 in A549 cells (Supplementary Fig. 7H). All these results suggest that the intracellular domain of CD147 interacts with the C-terminal tail of RanBP1.

CD147 regulates paclitaxel response via RanBP1 in vivo

To further investigate the in vivo role of RanBP1 in CD147-modulated paclitaxel response, we performed a xenograft assay in immunodeficient mice with cells from the ovarian cancer cell line SK-OV-3 expressing CD147<sup>ICD</sup> and/or shRNAs targeting RanBP1 (shRanBP1). When treated with paclitaxel, we found that CD147 overexpression group had less sensitive to paclitaxel compared with the control group. Notably, silence of RanBP1 significantly sensitized the cells to paclitaxel and reversed the effects of CD147 overexpression on paclitaxel response (Fig. 8D–E and Supplementary Fig. 8D). Using cells from the NSCLC cell line A549 expressing CD147<sup>WT</sup> and/or shRanBP1 we repeated the experiment and obtained similar results (Supplementary Fig. 9). Further analysis showed that CD147 overexpression group had more Ki67 expression (Fig. 8F), indicating that the cells overexpressing CD147 were more resistant to paclitaxel. On the contrary, shRanBP1 group showed minimal Ki67 expression. All these data suggest that CD147-modulated paclitaxel response is mediated by RanBP1.

DISCUSSION

CD147 is a multifunctional oncogenic protein. We and others have shown that CD147 is involved in chemotherapy response and resistance. CD147 silencing increased the sensitivity of cancer cells to 5-fluorouracil in breast cancer [27] and oral squamous carcinoma cells [20]. CD147 inhibited hepatocellular carcinoma cell apoptosis and decreased adriamycin chemosensitivity by inducing the unfolded protein response [19]. Anti-CD147 antibody sensitized pancreatic cancer cells to gemcitabine and gemcitabine/nitinib by blocking CD44s-signal transducer and activator of transcription 3 signaling [28]. CD147 was identified as a strong independent prognostic factor for response and survival after cisplatin-containing chemotherapy in patients with advanced bladder cancer [29]. The expression of CD147 and Lewis y antigen was an independent risk factor for paclitaxel and carboplatin resistance in ovarian cancer [30]. In the present study, we provide several lines of evidence demonstrating the involvement of CD147 in regulating cancer cell sensitivity to paclitaxel: (a) CD147 expression in ovarian cancer and NSCLC tissues correlates with pathological response of tumors to paclitaxel-based treatment; (b) CD147 expression increases in paclitaxel resistant cells compared with the parent cells, though the mechanism underlying CD147 upregulation remains to be elucidated; and (c) depletion of CD147 increases paclitaxel sensitivity and overexpression of CD147 has the opposite effect. Our results suggest a possibility of improving the pathological response to paclitaxel through modulating CD147 expression.

Paclitaxel is a potent mitotic poison, which binds to β-tubulin in the α-β-tubulin heterodimer and suppresses spindle microtubule

SPRINGER NATURE Oncogene (2022) 41:983 – 996
Fig. 6 CD147ICD interacts with RanBP1. A MS/MS confirmation of a RanBP1 peptide. B Western blot analyses of endogenous CD147 co-immunoprecipitated with endogenous RanBP1 in SK-VO-3 cells. IgG was used as a control antibody for immunoprecipitation. C Representative images of immunofluorescent staining of endogenous CD147 and RanBP1 in A549 cells. Scale bar = 10 μm. D SPR diagram of RanBP1 protein bound to CD147ICD. The KD values were calculated by the ProteOn Manager Software. E–F The interaction between the indicated constructs was analyzed with FRET. The color bar represents the FRET ratio. Scale bar, 10 μm. The graphs show FRET efficiencies. The p values were determined by two-tailed Student’s t test.
Fig. 7  CD147 regulates tubulin stability via RanBP1. A–B Western blot analysis of the indicated proteins in SK-OV-3 (A) and A549 (B) cells treated with or without 0.1 μM paclitaxel. Cell were transfected with CD147-pcDNA3.1 or vector alone, or in combination with either siRNA targeting RanBP1 (siRanBP1) or scramble siRNA. The graphs show semi-quantitative analysis of relative protein expression. The p values were determined by using two-tailed Student’s t test. C FRAP assay analysis of mobility fraction. The p values were determined by one-way ANOVA with Tukey’s post hoc test.
Dynamics, causing a delay or block at the metaphase-anaphase transition during mitosis. Disruption of the mitotic spindle dose not satisfy the spindle assembly checkpoint, which causes an extended mitotic arrest that can lead to cell death [31]. Given the preliminary pharmacological mechanism of paclitaxel, it is not surprising to speculate that proteins with regulatory effects on microtubule dynamics and/or spindle assembly may antagonize or synergize the anti-tumor activity of paclitaxel, and the dysregulation of these proteins may contribute to the variable response to paclitaxel treatment. Actually, previous work has shown that microtubule dynamics of cancer cells have a profound effect on the magnitude of paclitaxel response. For example, inactivation of tyrosine-protein kinase Fer increases microtubule stability in ovarian cancer cells, potentiating the cytotoxicity of paclitaxel [32]. Downregulation of PI3K-C2α causes spindle alterations and increases sensitivity to taxane-based therapy [33]. Here, we provide another example, CD147 decreases microtubule stability and supports resistance to paclitaxel treatment (Fig. 8G).

Ras-related nuclear protein (Ran) is a small GTPase that controls multiple cellular processes, including mitotic spindle assembly [37]. The Ran gradient is highly regulated during mitosis. After mitotic nuclear membrane breakdown, regulator of chromosome condensation (RCC1) generates Ran-GTP near mitotic chromosomes, while the majority of Ran distal to chromosomes is GDP-bound [38]. The presence of a mitotic Ran-GTP gradient directs proper spindle assembly by releasing spindle assembly factors in a spatially regulated manner [39]. RanBP1, a Ran-GTP binding protein found in many eukaryotes, stimulates RanGAP1’s activity roughly tenfold within in vitro assays using purified proteins [40]. It also promotes Ran-GTP release from karyopherin, thereby further enhancing RanGAP1-activated GTP hydrolysis on Ran [41, 42]. Structure analysis of the Ran-RanBP1-RanGAP ternary complex indicates that RanBP1 does not directly modify the dynamics, causing a delay or block at the metaphase-anaphase transition during mitosis.
properties of RanGAP and it functions by relieving the inhibition of
RanGAP by the C terminus of Ran [43]. RanBP1 can form a stable
heterotrimeric complex with Ran and RCC1 in vitro, inhibiting
RCC1’s nucleotide exchange activity [40]. Recent studies indicate
that RanBP1 promotes accurate chromosome segregation through
maintenance of optimal Ran-GTP gradients during mitosis in
mammalian cells [44]. In the present study, we demonstrated that
CD147ICD directly interacted with the C-terminal tail of RanBP1 and
overexpression of CD147 leads to the decreased abundance of
Ran-GTP. One possible explanation could be that CD147 binds to
the C-terminal tail of RanBP1 and induces conformation change of
RanBP1, resulting in increased association between Ran and
RanBP1 and promoting disinhibition of RanGAP. However, more
conclusive evidence of RanBP1 conformation change induced by
CD147 binding depends on structural studies.

In conclusion, we revealed that enhanced expression of CD147
regulated microtubule stability and dynamics via interacting with
the C-terminal tail of RanBP1, which contributed to reduced
sensitivity to paclitaxel treatment. Moreover, the in vitro and in vivo
results may provide a rational for decreasing CD147 as a new
therapeutic strategy to enhance sensitivity to paclitaxel-containing
chemotherapy.

MATERIALS AND METHODS

Cell lines

The A549 and SK-OV-3 cell lines were purchased from American Type
Culture Collection and cultured in RPMI 1640 medium supplemented
with 10% fetal bovine serum. CD147 knockdown and RanBP1 knockdown
stable cell lines were generated using lentivirus and the stable cell pool
was used for biological assays. The target sequences were depicted in
Supplementary Table 4. CD147 overexpression cells were generated by
transfecting cells with CD147/pDNA3.1(+) (+). Cells stably expressing EGFP-
tagged α-tubulin were generated by transfecting cells with α-tubulin/
EGFP-N1. The paclitaxel resistant A549 cells (A549-R) and SK-OV-3 cells
tagged with 10% fetal bovine serum. CD147 knockdown and RanBP1 knockdown
Culture Collection and cultured in RPMI 1640 medium supplemented
with 10% fetal bovine serum. CD147 knockdown and RanBP1 knockdown
stable cell lines were generated using lentivirus and the stable cell pool
was used for biological assays. The target sequences were depicted in
Supplementary Table 4. CD147 overexpression cells were generated by
transfecting cells with CD147/pDNA3.1(+) (+). Cells stably expressing EGFP-
tagged α-tubulin were generated by transfecting cells with α-tubulin/
EGFP-N1. The paclitaxel resistant A549 cells (A549-R) and SK-OV-3 cells
(SK-OV-3-R) were generated by challenging the cells with increasing
amounts of paclitaxel. CCK-8 assays were performed to confirm resistance to
paclitaxel. All cells were cultured at 37 °C and with 5% CO2.

Apoptosis and cell cycle assays

Apoptosis and cell cycle rates were assessed using an Annexin V-FITC/
propidium iodide apoptosis detection kit and a cell cycle detection kit,
respectively (KeyGEN Biotech, Nanjing, China). Quantification of propidium
iodide and FITC signals was performed using a fluorescence activated cell
sorter FACS Aria system (BD Bioscience, NJ, USA).

TUNEL staining

TUNEL staining was performed using the one-step TUNEL apoptosis kit
(Beyotime) according to the manufacturer’s instructions. The cells with
green fluorescence were defined as apoptotic cells. The percentage of
TUNEL-positive cells relative to DAPI-stained cells was calculated.

RNA sequencing

Total RNA was extracted using Trizol (TIANGEN, Shanghai, China).
Sequence libraries were generated and sequenced by BGI (Shenzhen,
China). The clean reads were subsequently aligned to the reference
genome using HISAT2 (Johns Hopkins University, MD, USA) with default
parameters. The processed reads from each sample were aligned using
HISAT (Johns Hopkins University) against the corresponding human
reference genome. Gene expression analyses were performed using
Cuffquant and Cuffnorm (Cufflinks 2.2.1). Cuffdiff was used to analyze the
DEGs between samples. The parameters for classifying significantly
DEGs was ≥2-fold difference (|log2FC| ≥ 1, FC: fold change of expres-
sion) in transcript abundance. Gene set enrichment analysis was
performed using Gene Set Enrichment Analysis software version 4.0.3
[45].

Protein purification

The DNA sequence encoding CD147ICD (residues 231–269) was subcloned
into the pET21a vector (Merck, NJ, USA) with a SUMO-His tag at
the C-terminus. Escherichia coli strain BL21 (DE3) harboring the construct
was cultured in LB medium with ampicillin (50 μg/mL) at 37 °C until the
OD600 = 0.6, and protein expression was induced with 100 μM IPTG at
18 °C overnight. The cells were lysed by freeze-thaw cycles followed by
sonication. After centrifugation, the supernatant was applied to HisTrap
HP column (GE, MA, USA). The SUMO tag was removed by overnight
digestion with Ulp1 protease. The proteins were further purified through
size exclusion chromatography on a Superdex 75 column (GE) in 50 mM
PBS (pH 7.5).

The DNA sequence encoding full-length RanBP1 was subcloned into the
pMal-c5x vector (NEB, MA, USA) to generate RanBP1 protein with an
N-terminal soluble MBP tag that promotes recombinant protein secretion
to the periplasm. The Escherichia coli strain BL21 (DE3) harboring the
construct was cultured in LB medium at 37 °C until OD600 = 0.6, and
protein expression was induced with 26.64 μM arabinose for 6 h at 37 °C.
The cells were harvested by centrifugation, resuspended in binding buffer
(20 mM Tris-HCl, 200 mM NaCl, and 1 mM EDTA, pH 7.4), and lysed by
freeze-thaw cycles followed by sonication. After centrifugation,
the supernatant was applied to an MBPTrap HP column (GE). After digestion
with thrombin (JingKe, Beijing, China), proteins were further purified through
size exclusion chromatography on a Superdex 75 column (GE) in
50 mM PBS (pH 7.5).

996
G. Nan et al.
Oncogene (2022) 41:983 – 996

SPRINGER NATURE
SPR studies were performed using a ProteOn XPR36 (Bio-Rad) instrument according to a One-shot Kinetics protocol. A concentration series of CD147Cys was injected over the immobilized ligand. Inclusion of the analyte diluted in TBS-T was done in the horizontal direction at 50 nL/min for 3 min. An equivalent buffer injection was used for reference subtraction. The dissociation time was set to 12 min. Equilibrium and rate constants were calculated using ProteOn Manager Software.

FRET assay
Three sequential images were acquired in the same field with suitable filter sets for the donor (EGFP; excitation at 488 nm and emission at 515 nm), acceptor (DsRed; excitation at 543 nm and emission at 585 nm), and FRET (excitation at 488 nm and emission at 585 nm). FRET calibration and net FRET were calculated using analysis software (Nikon, Tokyo, Japan).

Immunofluorescence staining
Cells were harvested and allowed to attach for 24 h to cell culture dishes with glass bottoms (NEST, Wuxi, China). After being washed twice with PBS, the cells were fixed in paraformaldehyde in PBS, permeabilized with 0.1% Triton X-100, and blocked with 2% bovine serum albumin in PBS for 1 h. The cells were then incubated with the indicated primary antibodies for 1 h; washed twice with PBS, and incubated with the appropriate secondary antibodies according to the manufacturer’s instructions. Cell nuclei were stained with DAPI (Vector Labs, CA, USA). After washing, the cells were visualized using an A1R-A1 confocal laser microscope system (Nikon).

Co-IP assay
Co-IP assay was performed using a Co-IP kit (ThermoFisher, MA, USA) as previously described [46]. Briefly, 15 µg of affinity-purified antibody was coupled to the resin. The antibody-agarose beads were mixed with the lysate, and the mixture was incubated with gentle agitation for 1 h. After washing the bead pellet three times with 1x Assay Buffer, the bead pellet was resuspended in 40 µL 2x reducing SDS-PAGE sample buffer. The pull-down supernatant was analyzed by western blot.

FRAP assay
FRAP was performed as previously described [47]. Briefly, A549 cells were transfected with a plasmid expressing GFP-tubulin, and multiple positive clones were pooled for further expansion. Photobleaching procedures were performed using an A1R-A1 confocal laser microscope system (Nikon). Regions of interest were bleached for 10 s followed by 2 min of observation, with image acquisition every 2 s. At least 20 observations were recorded per sample, and the recovered fluorescence intensities were normalized against background and unbleached regions within the cell of interest.

Xenograft tumor model
All animal protocols were approved by the Animal Care and Welfare Committee of the Fourth Military Medical University. The investigator was not blinded during the experiment. Cells used for in vivo assays were infected with lentivirus expressing firefly luciferase (Genechem, Shanghai, China). Mice were randomly allocated among groups. In total, 2×10^6 cells in 0.1 mL RPMI 1640 medium were subcutaneously inoculated into the right posterior flank of male BALB/c nude mice (~20 g, n = 6 per group). Ten days later, the mice were treated with intraperitoneal injection of saline or paclitaxel (10 mg/g) 3 times/week for 4 weeks. At 1 h, 2 weeks and 4 weeks after treatment, the in vivo fluorescence images of the mice after they were anesthetized with isoflurane were acquired using the IVIS imaging system (PerkinElmer, MA, USA). After 4 weeks of treatment, the mice were anesthetized and euthanized by cervical dislocation, and the tumor tissues were analyzed by hematoxylin and eosin and immunohistochemical staining.

Statistical analyses
Quantitative results are presented as the mean ± SD. The sample size was determined based on our experience and no statistical method was used to predetermine the sample size. The normality of the data distributions was checked using the Shapiro–Wilk test. Statistical analyses are described for each panel. All reported p values were two-tailed, and p < 0.05 was considered statistically significant.

REFERENCES
1. Fruehauf JP, Manetta A. Use of the extreme drug resistance assay to evaluate mechanisms of resistance in ovarian cancer: taxol resistance and MDR-1 expression. Contrib Gynecol Obstet. 1994;19:39–52.
2. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem. 1997;272:1718–25.
3. Gonzalez-Garay ML, Chang L, Blade K, Menick DR, Cabral F. A beta-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance. J Biol Chem. 1999;274:23875–82.
4. He L, Yang CP, Horvitz SB. Mutations in beta-tubulin map to domains involved in regulation of microtubule stability in epithelio-resistant cell lines. Mol Cancer Ther. 2001;13:10–13.
5. Yim S, Cabral F, Veeraraghavan S. Amino acid substitutions at proline 220 of beta-tubulin confer resistance to paclitaxel and colcemid. Mol Cancer Ther. 2007;6:7298–806.
6. Yim S, Bhattacharya R, Cabral F. Mutants that confer paclitaxel resistance. Mol Cancer Ther. 2010;9:327–35.
7. Yin S, Zeng C, Hari M, Cabral F. Random mutagenesis of beta-tubulin defines a set of dispersed mutations that confer paclitaxel resistance. Pharm Res. 2012;29:3994–4006.
8. Nami B, Wang Z. Genetics and Expression Profile of the Tubulin Gene Superfamily in Breast Cancer Subtypes and Its Relation to Taxane Resistance. Cancers (Basel). 2018;10:2724.
9. Kanakkanthara A, Miller JH. MicroRNAs: novel mediators of resistance to microtubule-targeting agents. Cancer Treat Rev. 2013;39:161–70.
10. Inoue S, Salah-Eldin AE, Omoteyama K. Apoptosis and anticancer drug resistance. Hum Cell. 2001;14:211–21.
11. Orr GA, Verdier-Pinard P, McDaid H, Horvitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene. 2003;22:7280–95.
12. Muramatsu T, Basigin (CD147), a multifunctional transmembrane glycoprotein with various binding partners. J Biochem. 2016;159:481–90.
13. Li Y, Xu J, Chen L, Zhong WD, Zhang Z, Mi L, et al. HAB18G (CD147), a cancer-associated biomarker and its role in cancer detection. Histopathology. 2009;54:677–87.
14. Cui HY, Wang SJ, Miao JY, Fu ZG, Feng F, Wu J, et al. CD147 regulates cancer migration via direct interaction with Annexin A2 and DOCK3-beta-catenin-WAVE2 signaling. Oncotarget. 2016;7:5613–29.
15. Wang SJ, Chao D, Wei W, Nan G, Li P, Liu FL, et al. CD147 promotes collective invasion through cathepsin B in hepatocellular carcinoma. J Exp Clin Cancer Res. 2020;39:145.
16. Liang Q, Han Q, Huang W, Nan G, Xu BQ, Jiang JL, et al. HAB18G/CD147 regulates vinculin-mediated focal adhesion and cytoskeleton organization in cultured human hepatocellular carcinoma cells. PLoS ONE. 2014;9:e102496.
17. Xu J, Shen ZY, Chen XG, Zhang Q, Bian HJ, Zhu P, et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology. 2007;45:269–76.
18. Chen Y, Zhang H, Guo X, Horioka Y, Xing J, Chen Z. Upregulation of HAB18G/CD147 in activated human umbilical vein endothelial cells enhances angiogenesis. Cancer Lett. 2009;278:113–21.
19. Tang J, Guo YS, Zhang Y, Yu XL, Li L, Huang W, et al. CD147 induces UPR to inhibit apoptosis and chemosensitivity by increasing the transcription of Bip in hepato-cellular carcinoma. Cell Death Differ. 2012;19:1779–90.
20. Kuang YH, Chen X, Su J, Wu LS, Liao LQ, Li D, et al. RNA interference targeting the CD147 induces apoptosis of multi-drug resistant cancer cells related to XIAP deletion. Cancer Lett. 2009;276:189–95.
21. Gou X, Ru Q, Zhang H, Chen Y, Li L, Yang H, et al. HAB18G/CD147 inhibits starvation-induced autophagy in human hepatoma cell SMCC7721 with an involvement of Berlin 1 down-regulation. Cancer Sci. 2009;100:837–43.
22. Newman JR, Bohannan IA, Zhang W, Skipper JB, Grizzle WE, Rosenthal EL. Modulation of tumor cell growth in vivo by extracellular matrix metalloproteinase inducer. Arch Otolaryngol Head Neck Surg. 2008;134:1218–24.
23. Zou W, Yang H, Hou X, Zhang W, Chen B, Xin X. Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to paclitaxel in HD-8910P cells. Cancer Lett. 2007;248:211–8.
24. Kuang YH, Chen X, Su J, Wu LS, Li J, Chang J, et al. Proteome analysis of multidrug resistance of human oral squamous carcinoma cells using CD147 silencing. J Proteome Res. 2008;7:4784–91.

25. Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ, Milas L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst. 1996;88:1308–14.

26. Strobelt T, Swanson L, Korsmeyer S, Cannistra SA. BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci USA. 1996;93:1409–9.

27. Kang MJ, Kim HP, Lee KS, Yoo YD, Kwon YT, Kim KM, et al. Proteomic analysis reveals that CD147/EMMPRIN confers chemoresistance in cancer stem cell-like cells. Proteomics. 2013;13:1714–25.

28. Fan XY, He D, Sheng CB, Wang B, Wang LJ, Wu XQ, et al. Therapeutic anti-CD147 antibody sensitizes cells to chemoradiotherapy via targeting pancreatic cancer stem cells. Am J Transl Res. 2011;3:1543–54.

29. Als AB, Dyrskjot L, von der Maase H, Koed K, Mansilla F, Toldbod HE, et al. Empmin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res. 2007;13:4407–14.

30. Gao J, Hu Z, Liu J, Liu D, Wang Y, Cai M, et al. Expression of CD147 and Lewis y antigen in ovarian cancer and their relationship to drug resistance. Med Oncol. 2014;31:920.

31. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 2010;10:194–204.

32. Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, et al. Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nat Commun. 2018;9:476.

33. Gulluni F, Martini M, De Santis MC, Campa CC, Ghigo A, Margaria JP, et al. Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2alpha Scaffolding Function. Cancer Cell. 2017;32:444–59 e447.

34. Yong YL, Zhang RJ, Liu ZK, Wei D, Shang YK, Liu ZK, et al. Gamma-secretase components regulate Notch1 signaling pathway in hepatocellular carcinoma. J Pathol. 2019;249:255–67.

35. Wu B, Cui J, Yang XM, Liu ZY, Song F, Li L, et al. Cytoplasmic fragment of CD147 generated by regulated intramembrane proteolysis contributes to HCC by promoting autophagy. Cell Death Dis. 2017;8:e2925.

36. Hu Y, Wu Y. Effect of CD147 monoclonal antibody on paclitaxel resistance in HCE1 multicellular spheroids. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011;36:192–202.

37. Dasso M. The Ran GTPase: theme and variations. Curr Biol. 2002;12:R502–9.

38. Seewald MJ, Korner C, Wittinghofer A, Vetter IR. RanGAP mediates GTP hydrolysis without an arginine finger. Nature. 2002;415:662–6.

39. Cavazza T, Vernos I. The RanGTP Pathway: From Nucleo-Cytoplasmic Transport to Spindle Assembly and Beyond. Front Cell Dev Biol. 2015;3:82.

40. Bischoff FR, Krebber H, Smirnova E, Dong W, Ponstingl H. Co-activation of CRMP2 phosphorylation. Nat Commun. 2018;9:476.

41. Bischoff FR, Gorlich D. RanBP1 is crucial for the release of RanGTP from importin beta-related nuclear transport factors. FEBS Lett. 1997;419:249–54.

42. Lounsbury KM, Macara IG. Ran-binding protein 1 (RanBP1) forms a ternary complex with Ran and karyopherin beta and reduces Ran GTPase-activating protein (RanGAP) inhibition by karyopherin beta. J Biol Chem. 1997;272:251–5.

43. Seewald MJ, Korner C, Wittinghofer A, Vetter IR. RanGAP mediates GTP hydrolysis without an arginine finger. Nature. 2002;415:662–6.

44. You KC, Arnautov A, Aksenova V, Kaufhold R, Chen S, Dasso M. RanBP1 controls the Ran pathway in mammalian cells through regulation of mitotic RCC1 dynamics. Cell Cycle. 2020;19:1889–916.

45. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15454–50.

46. Cui HY, Wang SJ, Song F, Cheng X, Nan G, Zhao Y, et al. CD147 receptor is essential for TFF3-mediated signaling regulating colorectal cancer progression. Signal Transduct Target Ther. 2021;6:268.

47. Yu Y, Gaillard S, Phillip JM, Huang TC, Pinto SM, Tessarollo NG, et al. Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules. Cancer Cell. 2015;28:82–96.

ACKNOWLEDGEMENTS

This work was supported by the National Key Research and Development Program of China (2018YFA0109000), the National Postdoctoral Program for Innovative Talents (BX20180376), the State Key Laboratory of Cancer Biology (CBSKL2019Z216), the Discipline Promotion Foundation of Xijing Hospital (XJZ118MU92), the Natural Science Foundation of Shaanxi Province (2020M-326) and the National Natural Science Foundation of China (31601127, 82103360 and 82173244). We thank Ms Rui-Rui Yao and Ms. Wen Wen for paraffin section, Ms Tian-Jiao Zhang for mouse model establishment.

AUTHOR CONTRIBUTIONS

HYC and SJW conceived and designed the project. GN, SHZ, TW, and DC performed experiments and/or conducted data acquisition and analyses; RFT, WJW, XF, PL, TG, BW, XXS, and XC contributed technical/reagents materials, analytic tools, and/or grant support; HYC, SJW and ZNC prepared, wrote, reviewed, and/or revised the paper.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41388-021-02143-3.

Correspondence and requests for materials should be addressed to Zhi-Nan Chen, Shi-Jie Wang or Hong-Yong Cui.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021